
- /
- Supported exchanges
- / US
- / MNPR.NASDAQ
Monopar Therapeutics Inc (MNPR NASDAQ) stock market data APIs
Monopar Therapeutics Inc Financial Data Overview
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Monopar Therapeutics Inc data using free add-ons & libraries
Get Monopar Therapeutics Inc Fundamental Data
Monopar Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.5667
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Monopar Therapeutics Inc News

Monopar therapeutics director Tsuchimoto sells $356k in stock
Director Kim R. Tsuchimoto of Monopar Therapeutics (NASDAQ:MNPR), sold 8,904 shares of common stock on July 14, 2025. The shares were sold in multiple transactions at prices ranging from $40.00 to $40...


Monopar therapeutics director Starr sells $672k in stock
Christopher M. Starr, a director at Monopar Therapeutics (NASDAQ:MNPR), sold 16,800 shares of common stock on July 14, 2025. The company’s stock has shown remarkable performance, with a 1,057% retur...

Monopar therapeutics CEO Chandler Robinson sells $672k in stock
Chandler Robinson, Chief Executive Officer of Monopar Therapeutics (NASDAQ:MNPR), sold 16,800 shares of common stock on July 14, 2025, according to a recent SEC Filing. The shares were sold at prices ...

Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy
Monopar Therapeutics Inc. (NASDAQ:MNPR) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 23, Chardan analyst Keay Nakae began coverage of the company’s stock with a “B...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.